342 related articles for article (PubMed ID: 24913471)
21. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
22. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
Beaven AW; Diehl LF
Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
[TBL] [Abstract][Full Text] [Related]
23. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
[No Abstract] [Full Text] [Related]
24. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
[TBL] [Abstract][Full Text] [Related]
27. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
Garnock-Jones KP
Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
[TBL] [Abstract][Full Text] [Related]
29. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
[TBL] [Abstract][Full Text] [Related]
30. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
32. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
Broccoli A; Derenzini E; Pellegrini C; Narducci R; Stefani G; Casadei B; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):493-5. PubMed ID: 23726017
[No Abstract] [Full Text] [Related]
33. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
35. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
DeVita MD; Evens AM; Rosen ST; Greenberger PA; Petrich AM
J Natl Compr Canc Netw; 2014 Apr; 12(4):465-71. PubMed ID: 24717566
[TBL] [Abstract][Full Text] [Related]
36. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin.
Ansell SM
Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
[TBL] [Abstract][Full Text] [Related]
38. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
39. Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.
Onaka T; Kitagawa T; Kawakami C; Yonezawa A
Turk J Haematol; 2018 May; 35(2):135-136. PubMed ID: 29391331
[No Abstract] [Full Text] [Related]
40. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
